key: cord-0723750-sf17526n authors: Krantz, Matthew S.; Stone, Cosby A.; Rolando, Lori A.; Nobis, Ana E.; Koo, Grace; Corey, Kristen B.; Bluestein, Sara B.; Staso, Patrick J.; Campbell, Emily M.; Phillips, Elizabeth J. title: An Academic Hospital Experience Screening mRNA COVID-19 Vaccine Risk Using Patient Allergy History date: 2021-07-19 journal: J Allergy Clin Immunol Pract DOI: 10.1016/j.jaip.2021.07.010 sha: 4eab57d8ebdf4b23188ce1113aa4dc2679ead07b doc_id: 723750 cord_uid: sf17526n nan 48 on epidemiology and mechanisms. Higher than expected rates of anaphylaxis have been reported with the Pfizer-BioNTech 51 and Moderna mRNA COVID-19 vaccines when compared with historical vaccine 52 anaphylaxis trends. 1 While the mechanism for such reactions remains unclear, and 53 current anaphylaxis classification schemes may be overly sensitive, early interest has 54 been placed on polyethylene glycol (PEG) 2000 present in the lipid nanoparticle carrier 55 system of these mRNA COVID-19 vaccines. 2 In order to attempt to preempt allergic 56 reactions, use of mRNA COVID-19 vaccines has been contraindicated in patients with 57 known allergy to PEG and previously contraindicated in those with known allergy to 58 PEG derivatives such as polysorbate where small studies have suggested cross-59 reactivity with PEG. 3, 4 The Centers for Disease Control (CDC) have recommended 60 caution and avoidance of vaccination with these mRNA vaccines in those with history of 61 injectable medication or vaccine anaphylaxis where PEG and polysorbate may be 62 present as excipients, but these allergies are thought to be quite rare overall. 2-4 63 However, the effectiveness of risk stratification by allergy history is unknown and may 64 be stymied by creating unnecessary perception of mRNA COVID-19 vaccine risk and 65 hesitancy in patients, increased complexity for vaccination sites, and a referral burden 66 to allergists for pre-vaccination risk assessment. Therefore, we examined the outcomes 67 of screening mRNA COVID-19 vaccine risk using patient-reported anaphylaxis history at 68 a single academic hospital employee vaccination program. anaphylaxis. For those reporting high-risk allergy history, the median age was 40 years 109 (IQR, 30 -53 years) and 71% were female (3/31 individuals were missing age and sex 110 data) ( Table 1) . Of the 31 individuals with high-risk allergy history, 28 (90%) were 111 recommended to proceed to dose one of the Pfizer-BioNTech mRNA COVID-19 112 vaccine based on implicated cause known to not contain PEG or polysorbate or known 113 subsequent tolerance of a PEG or polysorbate containing medication or vaccine (Table 114 1 Our study demonstrates that a preexisting PEG/polysorbate allergy is likely to be 182 encountered rarely, and given that there is lack of knowledge on mechanisms of 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 Reports of Anaphylaxis After Receipt of mRNA 209 COVID-19 Vaccines in the US Allergic reactions to the first COVID-19 vaccine: a 213 potential role of Polyethylene glycol? Immediate 215 Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We 216 Have Recognized IgE in anaphylaxis associated with polyethylene glycol Tennessee Department of Health Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines | CDC 226 mRNA 229 Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current 230 Evidence and Suggested Approach The REDCap 233 consortium: Building an international community of software platform partners Acute Allergic Reactions to mRNA COVID-19 Vaccines ! Proceed with vaccination.! Provide a 30-minute observation period.! Proceed with vaccination.! Provide a 15-minute observation period.! Do NOT proceed with vaccination.! Refer patient to Drug Allergy Clinic